Standard least-squares regression is fundamentally incompatible with immunoassay method comparisons because it demands a perfect reference method—a benchmark that simply doesn’t exist in the real world. In diagnostic method validation, both the established reference assay and the new immunoassay are subject to random analytical imprecision. Ordinary least-squares (OLS) regression assumes the reference method (x‑variable) is error‑free and minimizes residuals only in the y‑direction, leading to biased slope and intercept estimates that can misrepresent the true relationship between the two tests. Deming regression, by contrast, explicitly accounts for measurement error in both methods, using the ratio of their variances (λ = CVx² / CVy²) to deliver an unbiased, rigorous evaluation of systematic proportional and constant bias.
The core problem is that OLS treats the reference method as ideal truth, while in practice every immunoassay contributes noise. Deming regression removes this artificial asymmetry by incorporating the known error structure of both assays, producing slope and intercept values that genuinely reflect the clinical agreement—or lack thereof—between the new test and the established method. Without this correction, validation studies risk claiming equivalence when a systematic bias is actually present, or falsely flagging a method that is truly aligned.
The Hidden Assumption That Sabotages Ordinary Least‑Squares Regression
The Unrealistic Demand for a Zero‑Error Reference
OLS regression is built on a mathematical premise: the independent variable (x) is measured without random error. In industrial or pure‑physics contexts this may approximate reality, but no existing clinical immunoassay meets that criterion. The reference method itself possesses an assay‑specific coefficient of variation (CV) and inherent batch‑to‑batch imprecision, just like the candidate IVD kit it is meant to test.
When you force a method comparison into OLS, you effectively declare that all uncertainty belongs to the new assay. This ignores the analytical noise in the reference—a violation of the true data structure that distorts the entire regression line.
The Consequence: A Systematically Flawed Comparison
That violation isn’t theoretical. It manifests as a downward bias in the slope estimate, meaning the proportional relationship between the two assays is systematically underestimated. The magnitude of the bias grows as the random error standard deviation of the reference method increases relative to the spread of analyte values. In practical terms, a slope bias of 5–10 % can easily go undetected, undermining confidence in the assay’s reported dynamic range and diagnostic concordance at clinical decision thresholds.
Because OLS regression is asymmetric—you get a different line if you swap which assay is on the x‑axis—the analysis becomes an artifact of your arbitrary axis assignment, not an objective property of the methods.
How Deming Regression Restores Objectivity
Accounting for Error on Both Sides of the Equation
Deming regression belongs to a class of functional relationship models designed for exactly this situation. Instead of minimizing vertical distances, it minimizes the sum of squared distances perpendicular to the regression line at an angle that reflects the ratio of measurement errors (λ). By incorporating the known or experimentally derived imprecision of both the comparative and test methods, Deming regression disentangles true systematic differences from shared random noise.
This means the resulting intercept quantifies constant bias independent of concentration, and the slope reveals proportional bias—the two error categories that clinical laboratories must control to avoid misclassification of patient results across the assay range.
The Symmetry That Clinical Validation Demands
A critical advantage for regulatory and diagnostic decision‑making is the mathematical symmetry of Deming regression. The line does not change if you assign one assay to the x‑axis and the other to the y‑axis. This neutrality removes the ambiguity of OLS and presents an unambiguous, commutative picture of method agreement. When paired with Bland‑Altman percent‑difference plots, Deming regression provides the definitive framework to judge whether the new immunoassay is clinically equivalent to the established method, free of concentration‑dependent bias in low‑ or high‑patient sub‑populations.
Why One‑Size‑Fits‑All Regression Fails Across the Assay Range
The Problem of Inconstant Measurement Uncertainty
Many immunoassay analytes span wide concentration ranges where random error is proportional to the analyte level rather than constant. Standard unweighted regression—whether OLS or unweighted Deming—assumes constant variance (homoscedasticity) across the entire range. When the data are heteroscedastic, unweighted models give disproportionate influence to high‑concentration points with larger absolute errors, potentially masking critical performance differences near the lower limit of quantitation.
Ignoring this can require 1.2 to 3.7 times more samples to achieve the same statistical certainty in slope estimation, making the validation study less efficient and more costly.
Weighted Deming: Giving Every Concentration Its Proper Voice
Weighted Deming regression corrects for this by assigning each data pair a weight inversely proportional to its squared standard deviation (variance). In practice, this often means using the known concentration‑dependent CV profile of each assay to down‑weight noisy high‑concentration points and amplify the contribution of precise low‑concentration measurements. The result is an unbiased slope and intercept estimate that remains reliable across the entire reportable range, directly supporting the linearity and trueness claims required for IVD kit technical validation.
Understanding the Trade‑offs
The Critical Need for Accurate Variance Ratios
Deming regression is only as good as the error ratio (λ) you feed it. If the variances of the two methods are not estimated carefully—through adequate replication studies or historical QC data—the λ parameter itself can introduce bias. In situations where reliable variance data are unavailable, Deming may become a “garbage in, garbage out” exercise. Running a sensitivity analysis on different plausible λ values can help gauge robustness, but poorly quantify λ is a genuine pitfall.
The Complexity Cost vs. Regulatory Confidence
Implementing Weighted Deming requires a deeper statistical engagement than clicking “OLS” in a spreadsheet. You need to characterise the variance function for each assay, calculate weights, and use specialised software. This added complexity demands statistical expertise and cross‑functional collaboration. However, for high‑risk immunological markers and submissions to regulatory bodies like the FDA or IVDR‑designated authorities, the investment returns documentation of trueness that withstands scrutiny—a trade‑off most diagnostic developers willingly accept.
Making the Right Choice for Your Validation Protocol
Your regression strategy should align with the assay’s error structure, the available variance data, and the regulatory context.
- If your primary focus is unbiased slope and intercept estimation for an immunoassay with stable, known imprecision: Unweighted Deming regression, applied with a solid λ from robust CV determination, is the minimal standard. It eliminates the asymmetric distortion of OLS and gives your team confidence that any detected proportional bias is real, not statistical artifact.
- If your assay covers a wide concentration range where random error is clearly proportional to concentration: Implement Weighted Deming regression using concentration‑specific variance weights. This avoids the inefficiency and potential bias of ignoring heteroscedasticity, ensuring that both low‑end clinical sensitivity and high‑end specificity are assessed equally.
- If you cannot reliably estimate the error ratio for the two methods: Consider running a Passing‑Bablok regression as a complementary robust approach while you invest in a controlled replication experiment to quantify the CVs needed for Deming. Do not fall back to OLS as a default.
Ultimately, replacing OLS with Deming—and weighting it when necessary—transforms your method comparison from a potentially misleading formality into a transparent, defensible statement of diagnostic equivalence. That shift is what separates a validated immunoassay from one that merely passes a statistical check.
Summary Table:
| Regression Method | Error Assumption | Symmetry | Primary IVD Application |
|---|---|---|---|
| Ordinary Least-Squares (OLS) | Minimizes error in Y only; assumes X is error-free | Asymmetric | Non-clinical settings with near-zero reference error (Unsuitable for IVDs) |
| Unweighted Deming | Accounts for constant random error in both X and Y | Symmetric | Method comparisons with stable variance across measurement range |
| Weighted Deming | Accounts for proportional, heteroscedastic error in X and Y | Symmetric | Wide dynamic ranges where measurement noise scales with concentration |
| Passing-Bablok | Non-parametric; no error distribution assumptions | Symmetric | Complementary robust approach when variance ratios (λ) cannot be quantified |
Accelerate Your Immunoassay Validation with CamelBio
Navigating complex statistical validations and optimizing immunoassay performance requires both reliable raw materials and rigorous methodology. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need high-performance antibodies and recombinant antigens or technical expertise to ensure seamless regulatory compliance, our team is dedicated to advancing your diagnostic pipeline.
Ready to bring your next-generation assay from concept to clinic? Contact CamelBio today to speak with our technical experts!